ScoreWhy is Ningbo Menovo Pharmaceutical Co., Ltd. ?
1
Poor Management Efficiency with a low ROCE of 4.73%
- The company has been able to generate a Return on Capital Employed (avg) of 4.73% signifying low profitability per unit of total capital (equity and debt)
2
The company is Net-Debt Free
- Poor long term growth as Net Sales has grown by an annual rate of 4.64% and Operating profit at -1.64% over the last 5 years
- The company is Net-Debt Free
- The company has been able to generate a Return on Equity (avg) of 7.75% signifying low profitability per unit of shareholders funds
3
Poor long term growth as Net Sales has grown by an annual rate of 4.64% and Operating profit at -1.64% over the last 5 years
4
Positive results in Jun 26
- OPERATING CASH FLOW(Y) Highest at CNY 200.45 MM
- NET PROFIT(9M) At CNY 73.22 MM has Grown at 39.65%
- INTEREST COVERAGE RATIO(Q) The company hardly has any interest cost
5
With ROE of 4.97%, it has a fair valuation with a 3.28 Price to Book Value
- Over the past year, while the stock has generated a return of 71.84%, its profits have risen by 56.4% ; the PEG ratio of the company is 1.2
- At the current price, the company has a high dividend yield of 0
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Ningbo Menovo Pharmaceutical Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Ningbo Menovo Pharmaceutical Co., Ltd. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Ningbo Menovo Pharmaceutical Co., Ltd.
77.9%
1.83
77.95%
China Shanghai Composite
3.23%
0.23
14.72%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
4.64%
EBIT Growth (5y)
-1.64%
EBIT to Interest (avg)
3.99
Debt to EBITDA (avg)
3.39
Net Debt to Equity (avg)
0.40
Sales to Capital Employed (avg)
0.37
Tax Ratio
25.16%
Dividend Payout Ratio
23.23%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
4.00%
ROE (avg)
7.75%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
66
Industry P/E
Price to Book Value
3.28
EV to EBIT
56.21
EV to EBITDA
33.51
EV to Capital Employed
2.69
EV to Sales
5.51
PEG Ratio
1.17
Dividend Yield
NA
ROCE (Latest)
4.79%
ROE (Latest)
4.97%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bullish
Moving Averages
Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend16What is working for the Company
OPERATING CASH FLOW(Y)
Highest at CNY 200.45 MM
NET PROFIT(9M)
At CNY 73.22 MM has Grown at 39.65%
INTEREST COVERAGE RATIO(Q)
The company hardly has any interest cost
DEBT-EQUITY RATIO
(HY)
Lowest at 14.26 %
NET SALES(Q)
Highest at CNY 521.17 MM
OPERATING PROFIT(Q)
Highest at CNY 99.65 MM
PRE-TAX PROFIT(Q)
Highest at CNY 57.28 MM
-2What is not working for the Company
RAW MATERIAL COST(Y)
Grown by 5.66% (YoY
CASH AND EQV(HY)
Lowest at CNY 1,284.41 MM
Here's what is working for Ningbo Menovo Pharmaceutical Co., Ltd.
Operating Cash Flow
Highest at CNY 200.45 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (CNY MM)
Net Sales
At CNY 521.17 MM has Grown at 33.27%
over average net sales of the previous four periods of CNY 391.07 MMMOJO Watch
Near term sales trend is very positive
Net Sales (CNY MM)
Net Profit
At CNY 73.22 MM has Grown at 39.65%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (CNY MM)
Net Sales
Highest at CNY 521.17 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (CNY MM)
Operating Profit
Highest at CNY 99.65 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (CNY MM)
Pre-Tax Profit
Highest at CNY 57.28 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (CNY MM)
Pre-Tax Profit
At CNY 57.28 MM has Grown at 63.52%
over average net sales of the previous four periods of CNY 35.03 MMMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (CNY MM)
Debt-Equity Ratio
Lowest at 14.26 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Depreciation
Highest at CNY 36.1 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (CNY MM)
Depreciation
At CNY 36.1 MM has Grown at inf%
period on period (QoQ)MOJO Watch
The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales
Depreciation (CNY MM)
Here's what is not working for Ningbo Menovo Pharmaceutical Co., Ltd.
Cash and Eqv
Lowest at CNY 1,284.41 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
Raw Material Cost
Grown by 5.66% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
